Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has released the first clinical findings regarding AJX-101, a type II JAK2 inhibitor developed by Ajax Therapeutics. Data from the Phase 1 study indicates that the drug, also referred to as AJ1-11095, reduced spleen size and alleviated symptoms in patients with previously treated myelofibrosis.
Coverage from outlets including BioSpace, Yahoo Finance, and Fierce Biotech highlights the drug's efficacy as a potential expansion of Lilly’s pipeline beyond obesity treatments. These reports emphasize that the findings are being presented at the 2026 EHA Annual Meeting, noting the clinical performance of the treatment among patients who had previously used type I JAK inhibitors.
Future developments hinge on subsequent clinical trial phases. Coverage does not yet specify a timeline for further testing or potential regulatory submissions for the therapy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 100d ago.
Quick answers
What is the primary function of the drug AJX-101?
It is a first-in-class type II JAK2 inhibitor designed to treat myelofibrosis.
How much did Eli Lilly pay for the acquisition of Ajax?
Eli Lilly acquired Ajax for $2.3 billion.
Where are these study results being shared?
The data is being presented at the 2026 EHA Annual Meeting.
Coverage (8)
- Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy BioSpace · 103d ago
- Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside Yahoo Finance · 103d ago
- Eli Lilly announces new data from Phase 1 AJX-101 study TipRanks · 103d ago
- Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment GuruFocus · 103d ago
- Lilly trial drug cuts spleen size, symptoms in myelofibrosis Stock Titan · 103d ago
- AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis OncLive · 103d ago
- Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting investor.lilly.com · 103d ago
- Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ Fierce Biotech · 103d ago
Topics
Related trends
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.